Antibody‐mediated complement activation in pathology and protection
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Antibody‐dependent complement activity is associated not only with autoimmune morbidity, but also with antitumor efficacy. In infectious disease, both recombinant monoclonal antibodies and polyclonal antibodies generated in natural adaptive responses can mediate complement activity to protective, therapeutic or disease‐enhancing effect. Recent advances have contributed to the structural resolution of molecular complexes involved in antibody‐mediated complement activation, defining the avid nature of participating interactions and pointing to how antibody isotype, subclass, hinge flexibility, glycosylation state, amino acid sequence and the contextual nature of the cognate antigen/epitope are all factors that can determine complement activity through impact on antibody multimerization and subsequent recruitment of complement component 1q. Beyond the efficiency of activation, complement activation products interact with various cell types that mediate immune adherence, trafficking, immune education and innate functions. Similarly, depending on the anatomical location and extent of activation, complement can support homeostatic restoration or be leveraged by pathogens or neoplasms to enhance infection or promote tumorigenic microenvironments, respectively. Advances in means to suppress complement activation by intravenous immunoglobulin (IVIG), IVIG mimetics and complement‐intervening antibodies represent proven and promising exploratory therapeutic strategies, while antibody engineering has likewise offered frameworks to enhance, eliminate or isolate complement activation to interrogate in vivo mechanisms of action. Such strategies promise to support the optimization of antibody‐based drugs that are able to tackle emerging and difficult‐to‐treat diseases by improving our understanding of the synergistic and antagonistic relationships between antibody mechanisms mediated by Fc receptors, direct binding and the products of complement activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425 · cited 1×
“Schlothauer et al.(127) Residual FccRI binding.”
ApoE attenuates unresolvable inflammation by complex formation with activated C1q
Yin, C., Ackermann, S., Ma, Z., Mohanta, S. K., Zhang, C., Li, Y., Nietzsche, S., Westermann, M., Peng, L., Hu, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0336-8 · Cited by 305 · cited 1×
“Apolipoprotein E was shown to selectively complex with activated C1q at picomolar affinity and inhibit its activity.(41) Lastly, IVIG has been extensively used in the clinic to suppress inflammation across a range of disorders.”
BackgroundIsotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
Cited by
The role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104
“, a weak but constant hydrolytic activation of C3), but the alternative pathway can amplify complement activation (via nascent C3b) first generated by the classical pathway (Figure 1) [26,27].”
BackgroundComplement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes
West, C., Federspiel, J. D., Rogers, K., Khatri, A., Rao-Dayton, S., Ocana, M. F., Lim, S., D'Antona, A. M., Casinghino, S., & Somanathan, S. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.018 · Cited by 39
“IgG and IgM are canonically the isotypes most associated with a strong complement activation.(34)”
Complement System Response to Adeno-Associated Virus Vector Gene Therapy
Kropf, E., Markusic, D. M., Majowicz, A., Mingozzi, F., & Kuranda, K. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.194 · Cited by 39
Metadata
- Authors
- Goldberg, B. S., & Ackerman, M. E.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2020-04
- Volume
- 98
- Issue
- 4
- Pages
- 305-317
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W3010278385
- Cited by
- 120
- References
- 4
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody‐mediated complement activation in pathology and protection. https://app.cochat.ai/papers/10.1111/imcb.12324
- The paper
- Goldberg, B. S., & Ackerman, M. E. (2020). Antibody‐mediated complement activation in pathology and protection. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12324
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.